Milestone Pharmaceuticals Inc Dossier - Source-backed chat

Milestone Pharmaceuticals Inc

MISTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.98

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.82Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $101.6M

Enterprise Value −$9M

Shares Outstanding 124.5M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Milestone Pharmaceuticals has transitioned into a commercial-stage biopharmaceutical company following the landmark FDA approval of CARDAMYST (etripamil) nasal spray on December 12, 2025. As the first self-administered, rapid-acting treatment option for paroxysmal supraventricular tachycardia (PSVT) in over 30 years, CARDAMYST addresses a significant unmet need for over two million Americans, offering an alternative to costly and stressful emergency department visits. While initial Q1 2026 product revenues of $0.2 million reflect a slow, early-stage rollout, commercial execution is gaining momentum with key formulary wins (such as Express Scripts and UnitedHealth) and a 60-person sales force. Backed by a robust cash balance of $184.2 million—providing an operational runway into the second half of 2027—and a clear pipeline expansion path via the newly initiated Phase 3 ReVeRa-301 trial in AFib-RVR, Milestone presents a compelling risk-reward profile at its current valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$6.33

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

CARDAMYST faces slow commercial adoption due to high out-of-pocket costs for patients, restrictive prior authorization requirements by payers, or reluctance among physicians to prescribe a self-administered nasal spray for cardiac arrhythmias. Product revenues fail to offset the high commercial launch expenses (which reached $15.8 million in Q1 2026), leading to an accelerated cash burn rate. Delays in onboarding clinical sites for the ReVeRa-301 trial push back the AFib-RVR timeline, forcing the company to raise capital under unfavorable market conditions before reaching profitability.

Base CaseCentral scenario

CARDAMYST achieves steady commercial adoption in the US, supported by expanding commercial insurance coverage (reaching over 50% of covered lives by late 2026). The 60-person sales force successfully drives pull-through among cardiologists and electrophysiologists, leading to a consistent ramp in quarterly prescriptions. Meanwhile, the Phase 3 ReVeRa-301 trial in AFib-RVR begins enrolling patients in H2 2026 on schedule, keeping the supplemental NDA pathway on track for a 2028 readout. Cash burn remains controlled, preserving the runway into late 2027 without requiring highly dilutive near-term equity financing.

Bull CaseUpside scenario

Rapid commercial adoption of CARDAMYST in the US driven by key formulary wins (e.g., Express Scripts) and successful sales force execution, combined with positive Phase 3 ReVeRa-301 data in AFib-RVR that expands the addressable market to over 3 million patients, triggering milestone payments and driving the company to profitability by 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class, FDA-approved self-administered nasal spray (CARDAMYST) for PSVT, targeting a market of over two million patients in the US.
Strong clinical data showing patients using CARDAMYST were twice as likely to convert to sinus rhythm and did so three times faster than placebo, with a 40% reduction in emergency department visits.
Robust balance sheet with $184.2 million in cash and short-term investments as of March 31, 2026, funded by a $75 million RTW royalty payment and ATM/warrant exercises, securing runway into H2 2027.
Significant pipeline expansion potential with the initiation of the Phase 3 ReVeRa-301 trial for AFib-RVR, leveraging the existing safety database and a supplemental NDA pathway.

Key Investment Risks

Commercial execution risk, as the company's financial success is heavily dependent on the market adoption and sales ramp of a single product (CARDAMYST).
Payer and reimbursement hurdles, including potential restrictive tiering or prior authorization requirements that could limit patient access.
High operational cash burn driven by commercial launch expenses ($15.8 million in Q1 2026) and clinical trial costs for the AFib-RVR program.
Clinical and regulatory risks associated with the development of etripamil for the secondary AFib-RVR indication.

Thesis Invalidation Triggers

Failure to secure or maintain favorable formulary coverage with major pharmacy benefit managers (PBMs).
A significant acceleration in cash burn that shortens the operational runway to mid-2027 or earlier, necessitating highly dilutive financing.
Severe safety signals or adverse events reported in the real-world post-marketing surveillance of CARDAMYST.
Major delays or negative clinical outcomes in the Phase 3 ReVeRa-301 trial for AFib-RVR.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.